Analysis updated Oct 24, 2026 — scores and signals refreshed daily.
Ekso Bionics Holdings, Inc. Common Stock (CHRN) stock research. Updated Oct 24, 2026. Q-Score 33/100 — Sell. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Sell (33.0) (grade D). Gem alpha score: 37.0. 30 signals analyzed (25 differentiated alt-data).
StoQuant's analysis of Ekso Bionics Holdings, Inc. Common Stock (CHRN) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
CHRN stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-27 | $22.20 | $20.00 | $20.26 |
| 2026-08-04 | $24.93 | $22.23 | $24.45 |
| 2026-08-12 | $21.30 | $19.80 | $20.79 |
| 2026-08-20 | $24.83 | $23.30 | $24.10 |
| 2026-08-28 | $22.22 | $18.54 | $18.74 |
| 2026-09-08 | $22.00 | $19.65 | $21.06 |
| 2026-09-16 | $18.78 | $17.90 | $18.65 |
| 2026-09-24 | $22.58 | $20.27 | $21.85 |
| 2026-10-02 | $20.93 | $19.10 | $19.21 |
| 2026-10-12 | $18.49 | $17.86 | $17.88 |
| 2026-10-20 | $16.18 | $14.67 | $15.76 |
How Ekso Bionics Holdings, Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. Common Stock | $56M | — |
| PDSB | PDS Biotechnology Corporation | $57M | — |
| BGM | BGM Group Ltd. | $59M | — |
| CUE | Cue Biopharma, Inc. | $54M | — |
| COAG | Hemab Therapeutics Holdings, Inc. Common Stock | $53M | — |
View all Health Care stocks by valuation and signals →
Ekso Bionics Holdings, Inc. Common Stock (CHRN) scores Sell (33.0), and the composite conceals a 76-point disagreement between its dimensions. It is strongest on competitive moat at 81, and weakest on technicals at 24 and AI Alpha (gem) at 5. A stock can carry competitive moat that high while AI Alpha (gem) sits at 5; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 81 |
| technicals | 24 |
| AI Alpha (gem) | 5 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Ekso Bionics Holdings, Inc. Common Stock (CHRN): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CHRN"><img src="https://stoquant.com/badge/CHRN.svg" alt="Ekso Bionics Holdings, Inc. Common Stock (CHRN) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.